North America Neuroendocrine Tumors Market - Industry Trends and Forecast to 2028

TABLE OF CONTENT

TABLE OF CONTENTS 1 INTRODUCTION 1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF THE NORTH AMERICA NEUROENDOCRINE TUMORS MARKET 1.4 CURRENCY AND PRICING 1.5 LIMITATIONS 1.6 MARKETS COVERED 2 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET: SEGMENTATION 2.1 MARKETS COVERED 2.2 GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 DBMR TRIPOD DATA VALIDATION MODEL 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.6 MULTIVARIATE MODELLING 2.7 CLASSIFICATION LIFELINE CURVE 2.8 DBMR MARKET POSITION GRID 2.9 VENDOR SHARE ANALYSIS 2.10 MARKET END USER COVERAGE GRID 2.11 SECONDARY SOURCES 2.12 ASSUMPTIONS 3 EXECUTIVE SUMMARY 4 PREMIUM INSIGHTS 5 PIPELINE ANALYSIS 6 PRICING ANALYSIS 7 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET: REGULATIONS 7.1 REGULATORY PROCEDURE IN THE U.S. 7.2 REGULATORY PROCEDURE IN CANADA 7.3 REGULATORY PROCEDURE IN EUROPE 7.4 REGULATORY PROCEDURE IN CHINA 7.5 REGULATORY PROCEDURE IN MIDDLE EAST AND AFRICA 8 COMPARITIVE ANALYSIS BETWEEN MONOCLONAL AND POLYCLONAL ANTIBODY 8.1 MONOCLONAL ANTIBODY 8.2 POLYCLONAL ANTIBODY 9 MARKET OVERVIEW 9.1 DRIVERS 9.1.1 INCREASED INCIDENCE OF NEUROENDOCRINE TUMOR CASES 9.1.2 TECHNOLOGICAL ADVANCEMENT FOR THE DETECTION OF NEUROENDOCRINE TUMORS 9.1.3 GROWTH IN THE NUMBER OF PRIVATE DIAGNOSTIC CENTERS AND TREATMENT PROVIDERS 9.1.4 PRESENCE OF TARGETED TREATMENT OPTIONS 9.1.5 FAVORABLE REIMBURSEMENT POLICIES 9.2 RESTRAINTS 9.2.1 HIGH CAPITAL INVESTMENTS & LOW BENEFIT-COST RATIO FOR BIOMARKERS AND ORPHAN DRUGS 9.2.2 LACK OF AWARENESS AMONG THE POPULATION 9.2.3 UNMET NEEDS AND ACCESS TO MEDICAL RESOURCES IN SEVERAL REGIONS 9.2.4 HIGH COST OF DIAGNOSIS 9.3 OPPORTUNITIES 9.3.1 INCREASED GOVERNMENT INITIATIVES 9.3.2 EMERGING THERAPIES & DEVELOPMENT IN TREATMENT 9.3.3 RISING COLLABORATIONS AMONG THE MARKET PLAYERS 9.4 CHALLENGES 9.4.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS 9.4.2 STRINGENT GOVERNMENT REGULATIONS FOR THE DEVELOPMENT OF NEUROENDOCRINE TUMOR DRUGS 10 IMPACT OF COVID 19 ON NORTH AMERICA NEUROENDOCRINE TUMORS MARKET 10.1 PRICE IMPACT 10.2 IMPACT OF DEMAND 10.3 IMPACT ON SUPPLY CHAIN: 10.4 STRATEGIC DECISIONS: 10.5 CONCLUSION: 11 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 11.1 OVERVIEW 11.2 NON-FUNCTIONAL NET 11.3 FUNTIONAL NET 12 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY SITE 12.1 OVERVIEW 12.2 GASTROINTESTINAL TRACT (GI) 12.3 LUNGS 12.4 PANCREAS 13 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY GRADE 13.1 OVERVIEW 13.2 GRADE 2 (INTERMEDIATE-GRADE TUMOR) 13.3 GRADE 3 (HIGH-GRADE TUMOR) 13.4 GRADE 1( LOW-GRADE TUMOR) 14 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY TYPE 14.1 OVERVIEW 14.2 DIAGNOSIS 14.2.1 BLOOD TEST 14.2.2 IMAGING TEST 14.2.2.1 CTSCAN 14.2.2.2 MRI 14.2.2.3 OTHERS 14.2.3 BIOPSY 14.2.4 URINE TEST 14.2.5 OTHERS 14.3 TREATMENT 14.3.1 SOMATOSTATIN ANALOGS 14.3.1.1 OCTREOTIDE 14.3.1.2 LANREOTIDE 14.3.2 TARGETED THERAPY 14.3.2.1 EVEROLIMUS 14.3.2.2 SUNITINIB 14.3.2.3 OTHERS 14.3.3 RADIATION THERAPY 14.3.3.1 EXTERNAL-BEAM RADIATION 14.3.3.2 INTERNAL-BEAM RADIATION 14.3.4 SURGERY 14.3.4.1 CHOLECYSTECTOMY 14.3.4.2 OTHERS 14.3.5 LIVER-DIRECTED TREATMENT 14.3.5.1 RADIO FREQUENCY ABLATION (RFA) 14.3.5.2 HEPATIC ARTERY EMBOLIZATION 14.3.5.3 RADIOEMBOLIZATION 14.3.6 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)/ LUTATHERA 15 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION 15.1 OVERVIEW 15.2 ORAL 15.2.1 TABLETS 15.2.2 PILLS 15.2.3 OTHERS 15.3 PARENTERAL 15.3.1 SUBCUTANEOUS 15.3.2 INTRAMUSCULAR 15.3.3 OTHERS 16 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY END USER 16.1 OVERVIEW 16.2 HOSPITALS 16.3 SPECIALITY CLINICS 16.4 RADIATION CENTERS 16.5 HOME HEALTHCARE 16.6 OTHERS 17 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL 17.1 OVERVIEW 17.2 DIRECT TENDER 17.3 HOSPITAL PHARMACY 17.4 RETAIL SALES 17.5 ONLINE PHARMACY 17.6 OTHERS 18 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY GEOGRAPHY 18.1 NORTH AMERICA 18.1.1 U.S. 18.1.2 CANADA 18.1.3 MEXICO 19 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET: COMPANY LANDSCAPE 19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 20 SWOT 21 COMPANY PROFILES 21.1 F. HOFFMANN-LA ROCHE LTD 21.1.1 COMPANY SNAPSHOT 21.1.2 REVENUE ANALYSIS 21.1.3 COMPANY SHARE ANALYSIS 21.1.4 PRODUCT PORTFOLIO 21.1.5 RECENT DEVELOPMENTS 21.2 BRISTOL-MYERS SQUIBB COMPANY 21.2.1 COMPANY SNAPSHOT 21.2.2 REVENUE ANALYSIS 21.2.3 COMPANY SHARE ANALYSIS 21.2.4 PRODUCT PORTFOLIO 21.2.5 RECENT DEVELOPMENTS 21.3 VIATRIS INC. 21.3.1 COMPANY SNAPSHOT 21.3.2 COMPANY SHARE ANALYSIS 21.3.3 PRODUCT PORTFOLIO 21.3.4 RECENT DEVELOPMENTS 21.4 THERMO FISHER SCIENTIFIC INC. 21.4.1 COMPANY SNAPSHOT 21.4.2 REVENUE ANALYSIS 21.4.3 COMPANY SHARE ANALYSIS 21.4.4 PRODUCT PORTFOLIO 21.4.5 RECENT DEVELOPMENTS 21.5 NOVARTIS AG 21.5.1 COMPANY SNAPSHOT 21.5.2 REVENUE ANALYSIS 21.5.3 COMPANY SHARE ANALYSIS 21.5.4 PRODUCT PORTFOLIO 21.5.5 RECENT DEVELOPMENTS 21.6 REGENERON PHARMACEUTICALS, INC. 21.6.1 COMPANY SNAPSHOT 21.6.2 REVENUE ANALYSIS 21.6.3 PRODUCT PORTFOLIO 21.6.4 RECENT DEVELOPMENTS 21.7 ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG) 21.7.1 COMPANY SNAPSHOT 21.7.2 REVENUE ANALYSIS 21.7.3 PRODUCT PORTFOLIO 21.7.4 RECENT DEVELOPMENTS 21.8 BIONANO GENOMICS 21.8.1 COMPANY SNAPSHOT 21.8.2 PRODUCT PORTFOLIO 21.8.3 RECENT DEVELOPMENTS 21.9 BIOSYNTHEMA INC. 21.9.1 COMPANY SNAPSHOT 21.9.2 PRODUCT PORTFOLIO 21.9.3 RECENT DEVELOPMENTS 21.10 CALLISTOPHARMA 21.10.1 COMPANY SNAPSHOT 21.10.2 PRODUCT PORTFOLIO 21.10.3 RECENT DEVELOPMENTS 21.11 ELI LILLY AND COMPANY 21.11.1 COMPANY SNAPSHOT 21.11.2 REVENUE ANALYSIS 21.11.3 PRODUCT PORTFOLIO 21.11.4 RECENT DEVELOPMENTS 21.12 EXACT SCIENCES CORPORATION 21.12.1 COMPANY SNAPSHOT 21.12.2 REVENUE ANALYSIS 21.12.3 PRODUCT PORTFOLIO 21.12.4 RECENT DEVELOPMENTS 21.13 GLAXOSMITHKLINE PLC 21.13.1 COMPANY SNAPSHOT 21.13.2 REVENUE ANALYSIS 21.13.3 PRODUCT PORTFOLIO 21.13.4 RECENT DEVELOPMENTS 21.14 HUTCHISON CHINA MEDITECH LIMITED 21.14.1 COMPANY SNAPSHOT 21.14.2 REVENUE ANALYSIS 21.14.3 PRODUCT PORTFOLIO 21.14.4 RECENT DEVELOPMENTS 21.15 IPSEN PHARMA 21.15.1 COMPANY SNAPSHOT 21.15.2 REVENUE ANALYSIS 21.15.3 PRODUCT PORTFOLIO 21.15.4 RECENT DEVELOPMENTS 21.16 ILLUMINA, INC. 21.16.1 COMPANY SNAPSHOT 21.16.2 REVENUE ANALYSIS 21.16.3 PRODUCT PORTFOLIO 21.16.4 RECENT DEVELOPMENTS 21.17 LUPIN 21.17.1 COMPANY SNAPSHOT 21.17.2 REVENUE ANALYSIS 21.17.3 PRODUCT PORTFOLIO 21.17.4 RECENT DEVELOPMENTS 21.18 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC. 21.18.1 COMPANY SNAPSHOT 21.18.2 REVENUE ANALYSIS 21.18.3 PRODUCT PORTFOLIO 21.18.4 RECENT DEVELOPMENTS 21.19 PFIZER INC. 21.19.1 COMPANY SNAPSHOT 21.19.2 REVENUE ANALYSIS 21.19.3 PRODUCT PORTFOLIO 21.19.4 RECENT DEVELOPMENTS 21.20 SUN PHARMACEUTICAL INDUSTRIES LTD. 21.20.1 COMPANY SNAPSHOT 21.20.2 REVENUE ANALYSIS 21.20.3 PRODUCT PORTFOLIO 21.20.4 RECENT DEVELOPMENTS 21.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. 21.21.1 COMPANY SNAPSHOT 21.21.2 REVENUE ANALYSIS 21.21.3 PRODUCT PORTFOLIO 21.21.4 RECENT DEVELOPMENTS 22 QUESTIONNAIRE 23 RELATED REPORTS